United States

USPTO Patent Granted for Hypopigmentation Skin Treatment

The USPTO has granted a new patent (US12582688B2) to the University of Pretoria for a topical composition containing an extract from Aspalathus linearis for treating hypopigmentation disorders of the skin. The patent covers specific compositions and methods of use for this treatment.

USPTO Patent Granted for Crocus and Cannabis Sativa Composition

The USPTO has granted a patent (US12582687B2) to ACTIV'INSIDE for a composition containing extracts of Crocus sativus and Cannabis sativa. The patent covers uses of this composition as a pharmaceutical product, food supplement, nutritional product, cosmetic product, or liquid for electronic cigarettes.

USPTO Patent Grant: Saccharides for Wound Repair and Antiviral Use

The USPTO has granted Fjord Biotech AS a patent (US12582685B2) for the use of saccharides derived from Prasinococcales for wound repair, fibrotic conditions, and viral infections. The patent covers specific polysaccharides with an average molecular weight between 1,000 and 40,000 kDa and their applications in antiviral compositions.

USPTO Patent Granted for Water Soluble Silicon Dioxide Formulation

The USPTO has granted a patent for a water-soluble silicon dioxide formulation developed by Christina Rahm Cook. The formulation is designed for use in pharmaceuticals and nutraceuticals, aiming to provide intracellular detoxification and replenishment for living organisms.

USPTO Patent Granted for Composition Controlling Pharmacokinetics

The USPTO has granted patent US12582669B2 for a composition and method to control pharmacokinetics, assigned to the KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION. The patent covers compositions containing a polyvalent cation as an active ingredient.

USPTO Grants Patent for Topical Cannabinoid Composition

The USPTO has granted a patent (US12582665B2) for a topical cannabinoid composition. The patent details a specific formulation designed for enhanced cannabinoid delivery and potential treatment of various conditions.

USPTO Patent Granted for Cyano-Substituted Pyridine Pyrimidine Compound

The USPTO has granted a patent (US12582654B2) to BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED for a cyano-substituted pyridine and pyrimidine compound. The patent covers the compound's preparation method and its application in developing drugs as kinase inhibitors, specifically targeting FGFR4 and mutant FGFR4V550L.

USPTO Patent Grant for Opioid Response Treatment

The USPTO has granted patent US12582647B2 to Purdue Pharma L.P. for a method of treating opioid-induced adverse pharmacodynamic responses by administering buprenorphine. The patent covers systems and methods related to this treatment.

USPTO Patent for Respiratory Infection Treatment with Tradipitant

The USPTO has granted a patent to Vanda Pharmaceuticals Inc. for a method of treating lower respiratory tract infections, including those caused by COVID-19 or influenza, using the drug tradipitant. The patent, filed in 2021, details the use of this NK-1 receptor antagonist.

USPTO Grants Patent for Cancer Treatment Pharmaceutical Composition

The USPTO has granted patent US12582638B2 to the Korea Advanced Institute of Science and Technology for a pharmaceutical composition containing an mTOR-signaling inhibitor for treating cancer. The patent, filed on February 19, 2021, claims a composition that inhibits cancer cell growth and has anticancer properties.